Avelumab and Merkel Cell Carcinoma: Clinical Evidence Review on Causation

From General Health Education to Targeted Risk Assessment

The legacy theme of general health and science information has historically provided broad educational content on wellness, disease prevention, and biomedical advances. This foundation established a baseline understanding of how environmental and biological factors interact to influence health outcomes. Within this context, the transition to occupational exposure concern begins by narrowing focus to specific therapeutic agents and their potential unintended consequences. Avelumab, a monoclonal antibody targeting PD-L1, has been approved for the treatment of Merkel cell carcinoma, a rare but aggressive skin cancer. Clinical evidence reviews examining the relationship between avelumab exposure and Merkel cell carcinoma causation have emerged as a critical area of inquiry. This pivot moves from general health education toward a more targeted examination of how pharmaceutical interventions may intersect with occupational or environmental risk factors. The concern centers on whether exposure to avelumab—whether through therapeutic administration or potential occupational contact in manufacturing or healthcare settings—could influence the development or progression of Merkel cell carcinoma. This shift reframes the discussion from passive health information consumption to active risk assessment in professional environments where such exposures may occur.

Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). This made avelumab the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing, with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab, have significantly improved treatment outcomes in metastatic disease, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, despite these advances, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Immune-Related Adverse Events and Causation Considerations

Avelumab functions by blocking PD-L1, thereby preventing the inhibition of T-cell activity and promoting an anti-tumor immune response. However, this mechanism can also lead to overactivation of the immune system, resulting in immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). One reported case describes hypercalcemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, and avelumab therapy was safely continued (https://pubmed.ncbi.nlm.nih.gov/31543781/). This case illustrates the potential for avelumab to trigger immune-mediated inflammatory conditions beyond typical irAEs. For patients who become refractory to avelumab, treatment options are limited. A retrospective study at three German academic sites evaluated five patients with metastatic MCC refractory to avelumab who were subsequently treated with combined ipilimumab and nivolumab (IPI/NIVO). Three out of five patients responded to combined IPI/NIVO according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study from the prospective skin cancer registry ADOREG similarly reported that immune checkpoint inhibition with ipilimumab plus nivolumab can be effective in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). These findings indicate that while avelumab is a key first-line therapy, a subset of patients will require alternative immunotherapeutic strategies.

Risk Context and Clinical Management

From a causation perspective, the relationship between avelumab exposure and MCC outcomes is complex. Avelumab is approved for treating MCC, not causing it. However, the drug’s mechanism of immune activation can lead to adverse events that may complicate the clinical course. The timeline between avelumab initiation and documented harm, such as immune-related adverse events, is variable. In the reported case of sarcoidosis reactivation, hypercalcemia developed during treatment and resolved with corticosteroids, allowing continuation of avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). For patients who progress on avelumab, the timeline of refractoriness is not precisely defined but is clinically evident when disease progression is documented during therapy. Risk considerations for affected patients include the adequacy of warnings regarding avelumab and MCC. The prescribing information for avelumab includes warnings about immune-mediated adverse events, but specific guidance on the risk of sarcoidosis reactivation or other rare inflammatory conditions may not be comprehensive. Patients should be monitored for signs of immune overactivation, including hypercalcemia, and managed with corticosteroids as appropriate. For those who become refractory to avelumab, the availability of alternative checkpoint inhibitor combinations, such as ipilimumab plus nivolumab, provides a potential salvage option, though data are limited to small retrospective series. In summary, avelumab is an effective therapy for metastatic MCC, with a well-characterized mechanism of action and a manageable safety profile. However, immune-related adverse events can occur, and approximately half of patients may not respond or may become refractory. For such patients, combination immunotherapy with ipilimumab and nivolumab has shown activity in small studies. Clinicians should remain vigilant for immune-mediated complications and consider alternative treatment strategies when avelumab fails.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is avelumab and how does it work in Merkel cell carcinoma?

Can avelumab cause Merkel cell carcinoma or worsen its progression?

Avelumab is approved for treating MCC, not causing it. However, its immune activation mechanism can lead to immune-related adverse events (irAEs) that may complicate the clinical course. There is no evidence that avelumab causes MCC; rather, it is used to treat the disease. Patients should be monitored for immune overactivation, such as hypercalcemia from sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/).

What are the treatment options if avelumab fails in Merkel cell carcinoma?

For patients who become refractory to avelumab, combination immunotherapy with ipilimumab and nivolumab has shown activity in small retrospective studies. A study of five patients reported three responses (https://pubmed.ncbi.nlm.nih.gov/33439294/), and the ADOREG registry also supports this approach (https://pubmed.ncbi.nlm.nih.gov/36450381/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.